Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 1.00 |
| ▸ | ESR1 | P03372 | 5/20 | 0.82 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | GAA | P10253 | 2/20 | 0.82 |
| ▸ | MAPT | P10636 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.82 |
| ▸ | G6PD | P11413 | 1/20 | 0.82 |
| ▸ | PKM | P14618 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | RAB9A | P51151 | 1/20 | 0.82 |
| ▸ | DAB2IP | Q5VWQ8 | 1/20 | 0.82 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.82 |
| ▸ | SHBG | P04278 | 2/20 | 0.75 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3972095 | 1.00 | CYP19A1 (1.00) | CYP19A1ESR1ESR2MEN1LMNA | |
| SCHEMBL15491309 | 0.90 | ESR1 (1.00) | CYP19A1ESR1ESR2MEN1LMNA | |
| SCHEMBL29565170 | 0.90 | ESR1 (1.00) | CYP19A1ESR1ESR2MEN1LMNA | |
| SCHEMBL13123058 | 0.90 | ESR1 (1.00) | CYP19A1ESR1ESR2MEN1LMNA | |
| SCHEMBL12027476 | 0.90 | ESR1 (1.00) | CYP19A1ESR1ESR2MEN1LMNA | |
| SCHEMBL225053 | 0.90 | ESR1 (1.00) | CYP19A1ESR1ESR2MEN1LMNA | |
| SCHEMBL6010005 | 0.90 | ESR1 (1.00) | CYP19A1ESR1ESR2MEN1LMNA | |
| SCHEMBL225052 | 0.90 | ESR1 (1.00) | CYP19A1ESR1ESR2MEN1LMNA | |
| SCHEMBL14498991 | 0.87 | CYP19A1 (1.00) | CYP19A1ESR1ESR2MEN1LMNA | |
| SCHEMBL4206797 | 0.87 | CYP19A1 (1.00) | CYP19A1ESR1ESR2MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1640009-A1 | Estrogenic compounds as antimitotic agents | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2006-03-29 | — | — | EP | claimed |
| EP-0713393-B1 | ESTROGENIC COMPOUNDS AS ANTI-ANGIOGENESIS AGENTS | CHILDRENS MEDICAL CENTER (US) | 2005-12-21 | — | — | EP | claimed |
| US-20040223983-A1 | Pharmaceutical preparations, use of these preparations and process for increasing the biovailability of pharmaceutical substances to be administered perorally | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-11-11 | — | — | US | claimed |
| US-20040072813-A1 | Estrogenic compounds as anti-mitotic agents | D AMATO ROBERT JOHN (US) | 2004-04-15 | — | — | US | claimed |
| US-20030236408-A1 | Estrogenic compounds as anti-mitotic agents | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2003-12-25 | — | — | US | claimed |
| US-20030195180-A1 | Estrogenic compounds as anti-mitotic agents | D AMATO ROBERT JOHN (US) | 2003-10-16 | — | — | US | claimed |
| US-20030096800-A1 | Estrogenic compounds as anti-mitotic agents | D AMATO ROBERT JOHN (US) | 2003-05-22 | — | — | US | claimed |
| US-20020165212-A1 | Estrogenic compounds as anti-mitotic agents | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2002-11-07 | — | — | US | claimed |
| US-20020119959-A1 | Estrogenic compounds as anti-mitotic agents | D AMATO ROBERT JOHN (US) | 2002-08-29 | — | — | US | claimed |
| EP-0713393-A4 | ESTROGENIC COMPOUNDS AS ANTI-MITOTIC AGENTS | CHILDRENS MEDICAL CENTER (US) | 2000-10-25 | — | — | EP | claimed |
| US-5661143-A | INHIBITS (DE)POLYMERIZATION OF TUBULIN TO FORM CELLULAR MICROTUBES; ANTICARCINOGENIC,-TUMOR, INFLAMMATORY AND WOUND HEALING AGENTS; IMMUNOLOGY; ANGIOGENESIS INHIBITORS | THE CHILDREN'S MEDICAL CENTER CORP. (US) | 1997-08-26 | — | — | US | claimed |
| EP-0713393-A1 | ESTROGENIC COMPOUNDS AS ANTI-MITOTIC AGENTS | The Children's Medical Center Corporation (US) | 1996-05-29 | — | — | EP | claimed |
| US-5504074-A | ADMINISTERING SUBSTITUTED ESTRANES TO SUPPRESS VASCULARIZATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1996-04-02 | — | — | US | claimed |
| WO-1995004535-A1 | ESTROGENIC COMPOUNDS AS ANTI-MITOTIC AGENTS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1995-02-16 | — | — | WO | claimed |
| US-4605649-A | Method of treatment of estrogen deficiency disease | LIEHR JOACHIM G | 1986-08-12 | — | — | US | claimed |
| EP-0147155-A2 | Improved method of preparing 2-Fluoro-17beta-estradiol | ELI LILLY AND COMPANY (US) | 1985-07-03 | — | — | EP | claimed |
| US-4522758-A | Method of preparing 2-fluoro-17β-estradiol | ELI LILLY AND COMPANY (US) | 1985-06-11 | — | — | US | claimed |
| EP-0117117-A1 | Improvements in or relating to the treatment of estrogen deficiency conditions | Liehr, Joachim Georg (US) | 1984-08-29 | — | — | EP | claimed |
| US-8273383-B2 | Administration of 2-methoxyestradiol or it derivatives such as colchicine or combretastatin A-4; for treating and/or preventing a pregnancy related disease; safer and more effective | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-09-25 | — | — | US | disclosed |
| EP-0117117-A1 | Improvements in or relating to the treatment of estrogen deficiency conditions | Liehr, Joachim Georg (US) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072813-A1 | Estrogenic compounds as anti-mitotic agents | NUMA1, CCNB1, CCNB3 | CYP19A1 54/4885ESR1 47/4885ESR2 50/4885 |
| US-20020165212-A1 | Estrogenic compounds as anti-mitotic agents | NUMA1, CCNB1, CCNB3 | CYP19A1 54/4885ESR1 47/4885ESR2 50/4885 |
| US-20020119959-A1 | Estrogenic compounds as anti-mitotic agents | NUMA1, CCNB1, CCNB3 | CYP19A1 54/4885ESR1 47/4885ESR2 50/4885 |
| US-20030236408-A1 | Estrogenic compounds as anti-mitotic agents | NUMA1, CCNB1, CCNB3 | CYP19A1 54/4885ESR1 47/4885ESR2 50/4885 |
| US-20030195180-A1 | Estrogenic compounds as anti-mitotic agents | NUMA1, CCNB1, CCNB3 | CYP19A1 54/4885ESR1 47/4885ESR2 50/4885 |
| US-20030096800-A1 | Estrogenic compounds as anti-mitotic agents | NUMA1, CCNB1, CCNB3 | CYP19A1 54/4885ESR1 47/4885ESR2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.